41 results
8-K
EX-99.1
RVMD
Revolution Medicines Inc
26 Feb 24
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
4:04pm
finalizing a recommended Phase 2 dose in NSCLC and PDAC.
The company is developing a more mature data package to support regulatory engagement for final
425
EQRX
EQRx, Inc.
23 Oct 23
Business combination disclosure
6:13am
expect that a package to support a broad approval will need to include sufficient data to demonstrate efficacy in each mutation subgroup. We have
DEFM14A
1gyb3vdow6
29 Sep 23
Proxy related to merger
4:19pm
424B3
18vlyrz89o2
29 Sep 23
Prospectus supplement
4:17pm
S-4/A
kuauqs8
27 Sep 23
Registration of securities issued in business combination transactions (amended)
5:25pm
S-4
u0mhqjdjltb
13 Sep 23
Registration of securities issued in business combination transactions
5:20pm
8-K
EX-1.1
8u8cts 1f6396qr4m
22 Jul 22
Other Events
4:02pm
DEF 14A
2v5u0ke4szmeexk1
28 Apr 21
Definitive proxy
4:33pm
424B4
t312fwqmy vywosceh
5 Feb 21
Prospectus supplement with pricing info
12:00am
DRS
wcdhkvr7
21 Jan 21
Draft registration statement
12:00am